Jump to content

Zoltan Vajo

Add links
From Wikipedia, the free encyclopedia

This is an old revision of this page, as edited by Magioladitis (talk | contribs) at 08:40, 28 April 2016 (clean up / migrated Persondata in Wikidata, removed: {{Persondata | NAME = Vajo, Zoltan | ALTERNATIVE NAMES = | SHORT DESCRIPTION = American geneticist | DATE OF BIRTH = | PLACE OF BIRTH = [[Buda using AWB (12006)). The present address (URL) is a permanent link to this revision, which may differ significantly from the current revision.

Zoltan Vajo is a Hungarian/American scientist, best known [1] for his contributions to the Human Genome Project, including cloning the COQ7 gene,[2] characterizing the human CLK-1 timing protein cDNA [3] and its potential effect on aging,[4] and research on the molecular and genetic background of skeletal dysplasias and fibroblast growth factor receptor 3 disorders, including Achondroplasia, SADDAN (severe achondroplasia with developmental delay and acanthosis nigricans), Thanatophoric dysplasia, Muenke coronal craniosynostosis and Crouzon syndrome [5] as well as more recently on genetically engineered insulin analog molecules, including their structure, metabolic effects and cellular processing [6] and the role of recombinant DNA technology in the treatment of diabetes.[7]

Vajo et al. in 1999 cloned COQ7 from human heart. They found that the predicted protein contains 179 amino acids, is mostly helical, and contains an alpha-helical membrane insertion. It has a potential N-glycosylation site, a phosphorylation site for protein kinase C and another for casein kinase II, and 3 N-myristoylation sites. Northern blot analysis detected 3 transcripts; a 1-kb transcript was predominant in heart, and a 3-kb transcript was predominant in skeletal muscle, kidney, and pancreas.[8]

Vajo et al. found in 2000 that alterations in venous reactivity to alpha- and beta-adrenergic, nitric oxide (NO)-dependent, and other drugs are present in many genetically determined and acquired conditions, such as hypertension, smoking, and aging.[9]

In 2001, Fawcett, Bennett, Hamel, Vajo and Duckworth showed that the effect of human insulin and its analogues on protein degradation vary significantly in different cell types and with different experimental conditions. The differences seen in the action of the insulin analogues cannot be attributed to binding differences only. Post-receptor mechanisms, including intracellular processing and degradation, must be also considered.[10] Since then, recombinant DNA technology and the use of insulin analogues has become a major part of the treatment of diabetes.[11]

More recently (2007-2012), Vajo et al. developed novel influenza vaccines based on reverse genetics technology, including vaccines against the H5N1 bird flu and the H1N1 swine flu viruses, as well as seasonal influenza.[12] In preparation for the influenza pandemic, Vajo and Jankovics showed that instead of the conventionally used split virion or subunit vaccines, lower doses of whole virus vaccines are able to induce sufficient immune responses even against newly emerged influenza virus strains in pediatric [13] adult [14] and elderly patients, without increasing the rate of adverse events.[15] This was achieved in part by using aluminum phosphate as an adjuvant. The technologies developed during the preparation for an influenza pandemic were successfully translated into the production of reduced dose, seasonal trivalent influenza vaccines.[16]

Selected publications

  • Vajo Z, King LM, Jonassen T, et al. (October 1999). "Conservation of the Caenorhabditis elegans timing gene clk-1 from yeast to human: a gene required for ubiquinone biosynthesis with potential implications for aging". Mammalian Genome. 10 (10): 1000–4. doi:10.1007/s003359901147. PMID 10501970.
  • Vajo Z, Dachman W, Szekacs B (May 2000). "Alterations of venous drug reactivity in humans: acquired and genetic factors". Angiology. 51 (5): 361–6. doi:10.1177/000331970005100502. PMID 10826852.{{cite journal}}: CS1 maint: multiple names: authors list (link)
  • Vajo Z, Francomano CA, Wilkin DJ (February 2000). "The molecular and genetic basis of fibroblast growth factor receptor 3 disorders: the achondroplasia family of skeletal dysplasias, Muenke craniosynostosis, and Crouzon syndrome with acanthosis nigricans". Endocrine Reviews. 21 (1): 23–39. doi:10.1210/er.21.1.23. PMID 10696568.{{cite journal}}: CS1 maint: multiple names: authors list (link)
  • Rustin P, Von Kleist-Retzow, J.-C, Vajo Z, Rotig A, Munnich A. (April 2000). "For debate: defective mitochondria, free radicals, cell death, aging-reality or myth-ochondria?". Mechanisms of Ageing and Development. 114 (3): 201–206. doi:10.1016/S0047-6374(00)00102-0. PMID 10802124.{{cite journal}}: CS1 maint: multiple names: authors list (link)
  • Vajo Z, Duckworth W. (March 2000). "Genetically engineered insulin analogs: Diabetes in the new millennium". Pharmacological Reviews. 52 (1): 1–9. PMID 10699152.
  • Vajo Z, Fawcet J, Duckworth W. (October 2001). "Recombinant DNA technology in the treatment of diabetes: insulin analogs". Endocrine Reviews. 22 (5): 706–17. doi:10.1210/er.22.5.706. PMID 11588149.{{cite journal}}: CS1 maint: multiple names: authors list (link)
  • Fawcett J, Hamel FG, Bennett RG, Vajo Z, Duckworth WC. (April 2001). "Insulin and analogue effects on protein degradation in different cell types. Dissociation between binding and activity". Journal of Biological Chemistry. 276 (15): 11552–8. doi:10.1074/jbc.M007988200. PMID 11116143.{{cite journal}}: CS1 maint: multiple names: authors list (link) CS1 maint: unflagged free DOI (link)
  • Vajo Z, Kosa L, Visontay I, Jankovics M, Jankovics I. (May 2007). "Inactivated whole virus influenza A (H5N1) vaccine". Emerg Infect Dis. 13 (5): 807–8. doi:10.3201/eid1305.061248. PMC 2738456. PMID 18044056.{{cite journal}}: CS1 maint: multiple names: authors list (link)
  • Vajo Z, Tamas F, Sinka L, Jankovics I. (January 2010). "Safety and immunogenicity of a 2009 pandemic influenza A H1N1 vaccine when administered alone or simultaneously with the seasonal influenza vaccine for the 2009-10 influenza season: a multicentre, randomised controlled trial". Lancet. 375 (9708): 49–55. doi:10.1016/S0140-6736(09)62039-0. PMID 20018367.{{cite journal}}: CS1 maint: multiple names: authors list (link)
  • Vajo Z, Wood J, Kosa L, Szilvasy I, Paragh G, Pauliny Z, Bartha K, Visontay I, Kis A, Jankovics I. (February 2010). "A single-dose influenza A (H5N1) vaccine safe and immunogenic in adult and elderly patients: an approach to pandemic vaccine development". J Virol. 84 (3): 1237–42. doi:10.1128/JVI.01894-09. PMC 2812344. PMID 19906909.{{cite journal}}: CS1 maint: multiple names: authors list (link)
  • Vajo Z, Kosa L, Szilvasy I, Pauliny Z, Bartha K, Visontay I, Kis A, Tarjan I, Rozsa N, Jankovics I. (December 2008). "Safety and immunogenicity of a prepandemic influenza A (H5N1) vaccine in children". Pediatric Infectious Disease Journal. 27 (12): 1052–6. doi:10.1097/INF.0b013e3181861dd7. PMID 18978514.{{cite journal}}: CS1 maint: multiple names: authors list (link),
  • Vajo Z, Tamas F, Jankovics I. (March 2012). "A reduced-dose seasonal trivalent influenza vaccine is safe and immunogenic in adult and elderly patients in a randomized controlled trial". Clinical and Vaccine Immunology. 19 (3): 313–8. doi:10.1128/CVI.05619-11. PMC 3294605. PMID 22219315.{{cite journal}}: CS1 maint: multiple names: authors list (link)

In the media

On CNN, July 29, 2007

The Doctors' Channel, December 23, 2008

The Daily Miner, April 16, 2010

The Daily Miner, July 12, 2010

References

  1. ^ OMIM - Online Mendelian Inheritance in Man. ID 601683. http://www.ncbi.nlm.nih.gov/omim/601683
  2. ^ NCBI - National Center for Biotechnology and Information http://www.ncbi.nlm.nih.gov/nuccore/AF053770.1
  3. ^ NCBI - National Center for Biotechnology and Information http://www.ncbi.nlm.nih.gov/nuccore/AF032900.1
  4. ^ Rustin P, Von Kleist-Retzow, J.-C, Vajo Z, Rotig A, Munnich A. (April 2000). "For debate: defective mitochondria, free radicals, cell death, aging-reality or myth-ochondria?". Mechanisms of Ageing and Development. 114 (3): 201–206. doi:10.1016/S0047-6374(00)00102-0. PMID 10802124.{{cite journal}}: CS1 maint: multiple names: authors list (link)
  5. ^ Vajo Z, Francomano CA, Wilkin DJ (February 2000). "The molecular and genetic basis of fibroblast growth factor receptor 3 disorders: the achondroplasia family of skeletal dysplasias, Muenke craniosynostosis, and Crouzon syndrome with acanthosis nigricans". Endocrine Reviews. 21 (1): 23–39. doi:10.1210/er.21.1.23. PMID 10696568.{{cite journal}}: CS1 maint: multiple names: authors list (link)
  6. ^ Vajo Z, Duckworth W. (March 2000). "Genetically engineered insulin analogs: Diabetes in the new millennium". Pharmacological Reviews. 52 (1): 1–9. PMID 10699152.
  7. ^ Vajo Z, Fawcet J, Duckworth W. (October 2001). "Recombinant DNA technology in the treatment of diabetes: insulin analogs". Endocrine Reviews. 22 (5): 706–17. doi:10.1210/er.22.5.706. PMID 11588149.{{cite journal}}: CS1 maint: multiple names: authors list (link)
  8. ^ Vajo Z, King LM, Jonassen T, et al. (October 1999). "Conservation of the Caenorhabditis elegans timing gene clk-1 from yeast to human: a gene required for ubiquinone biosynthesis with potential implications for aging". Mammalian Genome. 10 (10): 1000–4. doi:10.1007/s003359901147. PMID 10501970.
  9. ^ Vajo Z, Dachman W, Szekacs B (May 2000). "Alterations of venous drug reactivity in humans: acquired and genetic factors". Angiology. 51 (5): 361–6. doi:10.1177/000331970005100502. PMID 10826852.{{cite journal}}: CS1 maint: multiple names: authors list (link)
  10. ^ Fawcett J, Hamel FG, Bennett RG, Vajo Z, Duckworth WC. (April 2001). "Insulin and analogue effects on protein degradation in different cell types. Dissociation between binding and activity". Journal of Biological Chemistry. 276 (15): 11552–8. doi:10.1074/jbc.M007988200. PMID 11116143.{{cite journal}}: CS1 maint: multiple names: authors list (link) CS1 maint: unflagged free DOI (link)
  11. ^ Vajo Z, Fawcett J, Duckworth WC. (October 2001). "Recombinant DNA technology in the treatment of diabetes: insulin analogs". Endocr Rev. 22 (5): 706–17. doi:10.1210/er.22.5.706. PMID 11588149.{{cite journal}}: CS1 maint: multiple names: authors list (link)
  12. ^ Vajo Z, Wood J, Kosa L, Szilvasy I, Paragh G, Pauliny Z, Bartha K, Visontay I, Kis A, Jankovics I. (February 2010). "A single-dose influenza A (H5N1) vaccine safe and immunogenic in adult and elderly patients: an approach to pandemic vaccine development". J Virol. 84 (3): 1237–42. doi:10.1128/JVI.01894-09. PMC 2812344. PMID 19906909.{{cite journal}}: CS1 maint: multiple names: authors list (link)
  13. ^ Vajo Z, Kosa L, Szilvasy I, Pauliny Z, Bartha K, Visontay I, Kis A, Tarjan I, Rozsa N, Jankovics I. (December 2008). "Safety and immunogenicity of a prepandemic influenza A (H5N1) vaccine in children". Pediatric Infectious Disease Journal. 27 (12): 1052–6. doi:10.1097/INF.0b013e3181861dd7. PMID 18978514.{{cite journal}}: CS1 maint: multiple names: authors list (link),
  14. ^ Vajo Z, Kosa L, Visontay I, Jankovics M, Jankovics I. (May 2007). "Inactivated whole virus influenza A (H5N1) vaccine". Emerg Infect Dis. 13 (5): 807–8. doi:10.3201/eid1305.061248. PMC 2738456. PMID 18044056.{{cite journal}}: CS1 maint: multiple names: authors list (link),
  15. ^ Vajo Z, Tamas F, Sinka L, Jankovics I. (January 2010). "Safety and immunogenicity of a 2009 pandemic influenza A H1N1 vaccine when administered alone or simultaneously with the seasonal influenza vaccine for the 2009-10 influenza season: a multicentre, randomised controlled trial". Lancet. 375 (9748): 49–55. doi:10.1016/S0140-6736(09)62039-0. PMID 20018367.{{cite journal}}: CS1 maint: multiple names: authors list (link)
  16. ^ Vajo Z, Tamas F, Jankovics I. (March 2012). "A reduced-dose seasonal trivalent influenza vaccine is safe and immunogenic in adult and elderly patients in a randomized controlled trial". Clin Vaccine Immunol. 19 (3): 313–8. doi:10.1128/CVI.05619-11. PMC 3294605. PMID 22219315.{{cite journal}}: CS1 maint: multiple names: authors list (link),
Retrieved from "https://en.wikipedia.org/w/index.php?title=Zoltan_Vajo&oldid=717535776"